Lisata Therapeutics LSTA Director · filings 2026 to 2026
No transactions in the filings read; Form 144 notices are listed above.
Person · CIK 1188919
Ted W Love
Director at Lisata Therapeutics, Jazz Pharmaceuticals, Structure Therapeutics, Royalty Pharma and Gilead Sciences
Earlier: Seagen, Global Blood Therapeutics, Portola Pharmaceuticals, Amicus Therapeutics, Cascadian Therapeutics, Kalobios Pharmaceuticals, Santarus, Mast Therapeutics, Onyx Pharmaceuticals, Affymax, Bio Rad Laboratories and ARCA biopharma
Sold on Form 4$16.7M
Noticed on Form 144$373K
Bought on Form 4$2.3M
Companies17
Holdings now
As reported after the latest Form 3, 4 or 5 at each company.
How these figures work
Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.
| Company | Security | Held | Shares or units | As of |
|---|---|---|---|---|
| Lisata Therapeutics LSTA | Common Stock | Directly | 19,260 | Sep 17, 2026 · Filing · EDGAR |
| Lisata Therapeutics LSTA | Series C Non-Voting Convertible Preferred Stock into Common Stock | Directly | 2,270,316 | Sep 17, 2026 · Filing · EDGAR |
| Jazz Pharmaceuticals JAZZ | Ordinary Shares | Directly | 2,389 | Aug 31, 2026 · Filing · EDGAR |
| Structure Therapeutics GPCR | Share Option (right to buy) exercise $15.00, expires Jun 16, 2036, into Ordinary Shares | Directly | 39,453 | Jun 17, 2026 · Filing · EDGAR |
| Royalty Pharma RPRX | Class A Ordinary Shares | Directly | 58,393 | Jun 5, 2026 · Filing · EDGAR |
| Gilead Sciences GILD | Common Stock | Directly | 5,484 | Apr 30, 2026 · Filing · EDGAR |
| Gilead Sciences GILD | Non-qualified Stock Option (Right to Buy) exercise $130.84, expires Apr 30, 2036, into Common Stock | Directly | 4,884 | Apr 30, 2026 · Filing · EDGAR |
| Portola Pharmaceuticals | Common Stock | Directly | 15,575 | Jun 12, 2020 · Filing · EDGAR |
| Amicus Therapeutics | Common Stock | Directly | 131,000 | Jun 4, 2020 · Filing · EDGAR |
| Amicus Therapeutics | Stock Options (right to buy) exercise $12.81, expires Jun 4, 2030, into Common Stock | Directly | 18,574 | Jun 4, 2020 · Filing · EDGAR |
| Onyx Pharmaceuticals | Common Stock | Directly | 77,756 | Jul 25, 2012 · Filing · EDGAR |
| ARCA biopharma | Common Stock | Directly | 3,580 | May 30, 2008 · Filing · EDGAR |
Sold and noticed by quarter
Sold (Form 4) Noticed (Form 144) Bought (Form 4)
Quarterly totals as a table
| Quarter | Sold (Form 4) | Noticed (Form 144) | Bought (Form 4) |
|---|---|---|---|
| Q3 2026 | — | $373K | — |
| Q2 2020 | $3.4M | Not machine-readable | — |
| Q1 2020 | $6.8M | Not machine-readable | — |
| Q4 2019 | $6.1M | Not machine-readable | — |
| Q1 2017 | — | — | $98K |
| Q3 2015 | — | — | $200K |
| Q4 2012 | — | — | $2M |
| Q3 2012 | $388K | Not machine-readable | — |
| Q1 2008 | — | — | $19K |
Form 144 notices went onto EDGAR as structured data on April 13, 2023. Earlier notices were filed on paper and cannot be read here, so those quarters show no noticed amount.
Planned sales (Form 144) and the sales that followed
Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.
How we match
A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.
| Notice date | Noticed | Planned sale | Outcome | Links |
|---|---|---|---|---|
| Jazz Pharmaceuticals JAZZ · Etrade Financial · No 10b5-1 plan stated · 1 notice | ||||
| Aug 31, 2026 | 1,527 · ~$373K | Aug 31, 2026 | Not sold yet | Filing · EDGAR |
| Sales without a matching Form 144 · 21 sales No matching Form 144 found. Not every sale needs one: small sales and sales by people who are not affiliates are exempt. | ||||
| — | — | — | Notice not machine-readable Global Blood Therapeutics: Sold 40,000 at $80.00 on Apr 28, 2020 · $3.2M (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Global Blood Therapeutics: Sold 1,517 at $80.63 on Apr 27, 2020 · $122K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Global Blood Therapeutics: Sold 1,300 at $81.15 on Apr 27, 2020 · $105K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Global Blood Therapeutics: Sold 1,818 at $70.92 on Feb 18, 2020 · $129K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Global Blood Therapeutics: Sold 2,189 at $70.22 on Feb 18, 2020 · $154K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Global Blood Therapeutics: Sold 1,031 at $82.45 on Jan 22, 2020 · $85K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Global Blood Therapeutics: Sold 32,150 at $81.85 on Jan 22, 2020 · $2.6M (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Global Blood Therapeutics: Sold 6,819 at $81.01 on Jan 22, 2020 · $552K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Global Blood Therapeutics: Sold 523 at $83.56 on Jan 21, 2020 · $44K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Global Blood Therapeutics: Sold 10,166 at $82.78 on Jan 21, 2020 · $842K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Global Blood Therapeutics: Sold 29,311 at $81.98 on Jan 21, 2020 · $2.4M (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Global Blood Therapeutics: Sold 3,716 at $76.15 on Dec 6, 2019 · $283K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Global Blood Therapeutics: Sold 23,152 at $77.72 on Dec 6, 2019 · $1.8M (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Global Blood Therapeutics: Sold 6,800 at $76.78 on Dec 6, 2019 · $522K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Global Blood Therapeutics: Sold 6,332 at $75.73 on Dec 6, 2019 · $480K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Global Blood Therapeutics: Sold 6,750 at $75.39 on Dec 5, 2019 · $509K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Global Blood Therapeutics: Sold 8,525 at $74.66 on Dec 5, 2019 · $636K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Global Blood Therapeutics: Sold 996 at $74.08 on Dec 5, 2019 · $74K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Global Blood Therapeutics: Sold 12,442 at $75.35 on Dec 5, 2019 · $937K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Global Blood Therapeutics: Sold 11,287 at $74.62 on Dec 5, 2019 · $842K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Onyx Pharmaceuticals: Sold 5,241 at $73.97 on Jul 25, 2012 · $388K (10b5-1 plan) | Filing · EDGAR |
Every transaction, by company
Each Form 3, 4 and 5 transaction in plain words, newest first.
How these figures work
Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.
Jazz Pharmaceuticals JAZZ Director · filings 2025 to 2026 · $373K noticed on Form 144
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Aug 31, 2026 | Shares withheld for tax or exercise price | −6 | $244.06 | $1K | 3,126 direct | Filing · EDGAR |
| Aug 31, 2026 | Shares withheld for tax or exercise price | −737 | $241.39 | $178K | 2,389 direct | Filing · EDGAR |
| Aug 5, 2026 | Grant or award from the company | +1,605 | 3,132 direct | Filing · EDGAR | ||
| Feb 26, 2026 | Grant or award from the company | +1,527 | 1,527 direct | Filing · EDGAR |
Structure Therapeutics GPCR Director · filings 2023 to 2026
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Jun 17, 2026 | Grant or award from the company Share Option (right to buy) | +39,453 | 39,453 direct | Filing · EDGAR | ||
| Jun 23, 2025 | Grant or award from the company Share Option (right to buy) | +51,804 | 51,804 direct | Filing · EDGAR | ||
| Jun 25, 2024 | Grant or award from the company Share Option (right to buy) | +33,595 | 33,595 direct | Filing · EDGAR | ||
| Aug 3, 2023 | Grant or award from the company Stock option (right to buy) | +75,000 | 75,000 direct | Filing · EDGAR |
Royalty Pharma RPRX Director · filings 2020 to 2026
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Jun 5, 2026 | Grant or award from the company | +4,545 | 58,393 direct | Filing · EDGAR | ||
| May 13, 2025 | Grant or award from the company | +7,614 | 53,848 direct | Filing · EDGAR | ||
| Jun 7, 2024 | Grant or award from the company | +9,293 | 46,234 direct | Filing · EDGAR | ||
| Jun 23, 2023 | Grant or award from the company | +7,747 | 36,941 direct | Filing · EDGAR | ||
| Jun 24, 2022 | Grant or award from the company | +6,328 | 29,194 direct | Filing · EDGAR | ||
| Jun 25, 2021 | Grant or award from the company | +5,726 | 22,866 direct | Filing · EDGAR | ||
| Aug 13, 2020 | Grant or award from the company | +7,280 | 17,280 direct | Filing · EDGAR |
Gilead Sciences GILD Director · filings 2024 to 2026
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Apr 30, 2026 | Grant or award from the company | +1,146 | 5,484 direct | Filing · EDGAR | ||
| Apr 30, 2026 | Grant or award from the company Non-qualified Stock Option (Right to Buy) | +4,884 | 4,884 direct | Filing · EDGAR | ||
| May 7, 2025 | Grant or award from the company | +1,516 | 4,338 direct | Filing · EDGAR | ||
| May 7, 2025 | Grant or award from the company Non-qualified Stock Option (Right to Buy) | +6,809 | 6,809 direct | Filing · EDGAR | ||
| May 8, 2024 | Grant or award from the company | +2,310 | 2,822 direct | Filing · EDGAR | ||
| May 8, 2024 | Grant or award from the company Non-qualified Stock Option (Right to Buy) | +12,648 | 12,648 direct | Filing · EDGAR | ||
| Feb 2, 2024 | Grant or award from the company | +512 | 512 direct | Filing · EDGAR | ||
| Feb 2, 2024 | Grant or award from the company Non-qualified Stock Option (Right to Buy) | +2,996 | 2,996 direct | Filing · EDGAR |
Seagen Director · filings 2020 to 2023
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Dec 14, 2023 | Returned to the company | −4,255 | $229.00 | $974K | 0 direct | Filing · EDGAR |
| Dec 14, 2023 | Returned to the company Stock Options (Right to Buy) | −4,460 | 0 direct | Filing · EDGAR | ||
| Dec 14, 2023 | Returned to the company Stock Options (Right to Buy) | −3,462 | 0 direct | Filing · EDGAR | ||
| Dec 14, 2023 | Returned to the company Stock Options (Right to Buy) | −3,676 | 0 direct | Filing · EDGAR | ||
| Dec 14, 2023 | Returned to the company Restricted Stock Units | −449 | 0 direct | Filing · EDGAR | ||
| Dec 14, 2023 | Returned to the company Restricted Stock Units | −2,044 | 0 direct | Filing · EDGAR | ||
| May 31, 2023 | Grant or award from the company | +2,044 | 6,748 direct | Filing · EDGAR | ||
| May 13, 2022 | Grant or award from the company | +1,503 | 4,704 direct | Filing · EDGAR | ||
| May 13, 2022 | Grant or award from the company Non-Qualified Stock Option (right to buy) | +3,676 | 3,676 direct | Filing · EDGAR | ||
| May 14, 2021 | Grant or award from the company | +1,402 | 3,201 direct | Filing · EDGAR | ||
| May 14, 2021 | Grant or award from the company Non-Qualified Stock Option (right to buy) | +3,462 | 3,462 direct | Filing · EDGAR | ||
| Aug 17, 2020 | Grant or award from the company | +1,799 | 1,799 direct | Filing · EDGAR | ||
| Aug 17, 2020 | Grant or award from the company Non-Qualified Stock Option (right to buy) | +4,460 | 4,460 direct | Filing · EDGAR |
Global Blood Therapeutics President and CEO · filings 2015 to 2022 · sold $16.4M · bought $200K
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Oct 5, 2022 | Returned to the company | −576,318 | $0.00 | $576 | 0 direct | Filing · EDGAR |
| Oct 5, 2022 | Returned to the company | −119,650 | $0.00 | $120 | 0 By Trust 1 | Filing · EDGAR |
| Oct 5, 2022 | Returned to the company | −119,650 | $0.00 | $120 | 0 By Trust 2 | Filing · EDGAR |
| Oct 5, 2022 | Returned to the company | −102,000 | $0.00 | $102 | 0 By Trust 3 | Filing · EDGAR |
| Oct 5, 2022 | Returned to the company | −2,500 | $0.00 | $3 | 0 By Daughter | Filing · EDGAR |
| Oct 5, 2022 | Returned to the company | −2,500 | $0.00 | $3 | 0 By Daughter | Filing · EDGAR |
| Oct 5, 2022 | Returned to the company Restricted Stock Units | −11,250 | 0 direct | Filing · EDGAR | ||
| Oct 5, 2022 | Returned to the company Restricted Stock Units | −26,865 | 0 direct | Filing · EDGAR | ||
| Oct 5, 2022 | Returned to the company Restricted Stock Units | −47,223 | 0 direct | Filing · EDGAR | ||
| Oct 5, 2022 | Returned to the company Restricted Stock Units | −63,768 | 0 direct | Filing · EDGAR | ||
| Oct 5, 2022 | Returned to the company Restricted Stock Units | −109,116 | 0 direct | Filing · EDGAR | ||
| Oct 5, 2022 | Returned to the company Restricted Stock Units | −141,400 | 0 direct | Filing · EDGAR | ||
| Oct 5, 2022 | Returned to the company Stock Option (Right to Buy) | −114,515 | 0 direct | Filing · EDGAR | ||
| Oct 5, 2022 | Returned to the company Stock Option (Right to Buy) | −122,000 | 0 direct | Filing · EDGAR | ||
| Oct 5, 2022 | Returned to the company Stock Option (Right to Buy) | −145,000 | 0 direct | Filing · EDGAR | ||
| Oct 5, 2022 | Returned to the company Stock Option (Right to Buy) | −114,190 | 0 direct | Filing · EDGAR | ||
| Oct 5, 2022 | Returned to the company Stock Option (Right to Buy) | −132,433 | 0 direct | Filing · EDGAR | ||
| Oct 5, 2022 | Returned to the company Stock Option (Right to Buy) | −118,090 | 0 direct | Filing · EDGAR | ||
| Sep 27, 2022 | Option or RSU exercised or converted | +18,291 | $16.40 | $300K | 576,318 direct | Filing · EDGAR |
| Sep 27, 2022 | Option or RSU exercised or converted Stock Option (Right to Buy) | −18,291 | 114,515 direct | Filing · EDGAR | ||
| Sep 13, 2022 | Gift | −35,300 | 558,027 direct | Filing · EDGAR | ||
| Sep 13, 2022 | Gift | +17,650 | 119,650 By Trust 1 | Filing · EDGAR | ||
| Sep 13, 2022 | Gift | +17,650 | 119,650 By Trust 2 | Filing · EDGAR | ||
| Sep 9, 2022 | Gift | −221,200 | 593,327 direct | Filing · EDGAR | ||
| Sep 1, 2022 | Option or RSU exercised or converted | +9,444 | 814,618 direct | Filing · EDGAR | ||
| Sep 1, 2022 | Option or RSU exercised or converted | +9,109 | 823,727 direct | Filing · EDGAR | ||
| Sep 1, 2022 | Shares withheld for tax or exercise price | −9,200 | $68.15 | $627K | 814,527 direct | Filing · EDGAR |
| Sep 1, 2022 | Option or RSU exercised or converted Restricted Stock Units | −9,444 | 47,223 direct | Filing · EDGAR | ||
| Sep 1, 2022 | Option or RSU exercised or converted Restricted Stock Units | −9,109 | 63,768 direct | Filing · EDGAR | ||
| Aug 1, 2022 | Option or RSU exercised or converted | +20,205 | 815,192 direct | Filing · EDGAR | ||
| Aug 1, 2022 | Shares withheld for tax or exercise price | −10,018 | $32.40 | $325K | 805,174 direct | Filing · EDGAR |
| Aug 1, 2022 | Option or RSU exercised or converted Restricted Stock Units | −11,250 | 11,250 direct | Filing · EDGAR | ||
| Aug 1, 2022 | Option or RSU exercised or converted Restricted Stock Units | −8,955 | 26,865 direct | Filing · EDGAR | ||
| Mar 1, 2022 | Option or RSU exercised or converted | +9,445 | 799,061 direct | Filing · EDGAR | ||
| Mar 1, 2022 | Shares withheld for tax or exercise price | −4,074 | $29.87 | $122K | 794,987 direct | Filing · EDGAR |
| Mar 1, 2022 | Option or RSU exercised or converted Restricted Stock Units | −9,445 | 56,667 direct | Filing · EDGAR | ||
| Mar 1, 2022 | Grant or award from the company Restricted Stock Units | +72,877 | 72,877 direct | Filing · EDGAR | ||
| Mar 1, 2022 | Grant or award from the company Restricted Stock Units | +72,877 | 72,877 direct | Filing · EDGAR | ||
| Mar 1, 2022 | Grant or award from the company Stock Option (Right to buy) | +118,090 | 118,090 direct | Filing · EDGAR | ||
| Feb 28, 2022 | Grant or award from the company | +839 | $25.37 | $21K | 789,616 direct | Filing · EDGAR |
| Feb 1, 2022 | Option or RSU exercised or converted | +29,955 | 799,308 direct | Filing · EDGAR | ||
| Feb 1, 2022 | Shares withheld for tax or exercise price | −10,531 | $29.33 | $309K | 788,777 direct | Filing · EDGAR |
| Feb 1, 2022 | Option or RSU exercised or converted Restricted Stock Units | −9,750 | 0 direct | Filing · EDGAR | ||
| Feb 1, 2022 | Option or RSU exercised or converted Restricted Stock Units | −11,250 | 22,500 direct | Filing · EDGAR | ||
| Feb 1, 2022 | Option or RSU exercised or converted Restricted Stock Units | −8,955 | 35,820 direct | Filing · EDGAR | ||
| Sep 1, 2021 | Option or RSU exercised or converted | +9,444 | 798,857 direct | Filing · EDGAR | ||
| Sep 1, 2021 | Shares withheld for tax or exercise price | −4,683 | $29.85 | $140K | 794,174 direct | Filing · EDGAR |
| Sep 1, 2021 | Option or RSU exercised or converted Restricted Stock Units | −9,444 | 66,112 direct | Filing · EDGAR | ||
| Aug 1, 2021 | Option or RSU exercised or converted | +29,955 | 804,266 direct | Filing · EDGAR | ||
| Aug 1, 2021 | Shares withheld for tax or exercise price | −14,853 | $27.33 | $406K | 789,413 direct | Filing · EDGAR |
| Aug 1, 2021 | Option or RSU exercised or converted Restricted Stock Units | −9,750 | 9,750 direct | Filing · EDGAR | ||
| Aug 1, 2021 | Option or RSU exercised or converted Restricted Stock Units | −11,250 | 33,750 direct | Filing · EDGAR | ||
| Aug 1, 2021 | Option or RSU exercised or converted Restricted Stock Units | −8,955 | 44,775 direct | Filing · EDGAR | ||
| Mar 1, 2021 | Grant or award from the company Stock Option (Right to Buy) | +132,433 | 132,433 direct | Filing · EDGAR | ||
| Mar 1, 2021 | Grant or award from the company Restricted Stock Units | +75,556 | 75,556 direct | Filing · EDGAR | ||
| Feb 28, 2021 | Grant or award from the company | +370 | $36.21 | $13K | 774,311 direct | Filing · EDGAR |
| Feb 1, 2021 | Option or RSU exercised or converted | +42,018 | 791,834 direct | Filing · EDGAR | ||
| Feb 1, 2021 | Shares withheld for tax or exercise price | −17,893 | $49.49 | $886K | 773,941 direct | Filing · EDGAR |
| Feb 1, 2021 | Option or RSU exercised or converted Restricted Stock Units | −12,063 | 0 direct | Filing · EDGAR | ||
| Feb 1, 2021 | Option or RSU exercised or converted Restricted Stock Units | −9,750 | 19,500 direct | Filing · EDGAR |
93 earlier transactions are in the filing list below.
Portola Pharmaceuticals Director · filings 2019 to 2020
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Jul 2, 2020 | Returned to the company | −15,575 | $18.00 | $280K | 0 direct | Filing · EDGAR |
| Jul 2, 2020 | Returned to the company Stock Option (Right to Buy) | −11,377 | $0.06 | $683 | 0 direct | Filing · EDGAR |
| Jul 2, 2020 | Returned to the company Stock Option (Right to Buy) | −14,812 | 0 direct | Filing · EDGAR | ||
| Jun 12, 2020 | Grant or award from the company | +7,281 | 15,575 direct | Filing · EDGAR | ||
| Jun 12, 2020 | Grant or award from the company Stock Option (Right to Buy) | +11,377 | 11,377 direct | Filing · EDGAR | ||
| Sep 18, 2019 | Grant or award from the company | +8,294 | 8,294 direct | Filing · EDGAR | ||
| Sep 18, 2019 | Grant or award from the company Stock Option (Right to Buy) | +14,812 | 14,812 direct | Filing · EDGAR |
Amicus Therapeutics Director · filings 2012 to 2020
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Jun 4, 2020 | Grant or award from the company | +5,855 | 131,000 direct | Filing · EDGAR | ||
| Jun 4, 2020 | Grant or award from the company Stock Options (right to buy) | +18,574 | 18,574 direct | Filing · EDGAR | ||
| Jun 27, 2019 | Grant or award from the company | +6,250 | 125,145 direct | Filing · EDGAR | ||
| Jun 27, 2019 | Grant or award from the company Stock Options (right to buy) | +19,473 | 19,473 direct | Filing · EDGAR | ||
| Jun 7, 2018 | Grant or award from the company | +3,081 | 8,895 direct | Filing · EDGAR | ||
| Jun 7, 2018 | Grant or award from the company Stock Options (right to buy) | +8,912 | 8,912 direct | Filing · EDGAR | ||
| Jun 13, 2017 | Grant or award from the company | +5,814 | 147,814 direct | Filing · EDGAR | ||
| Jun 13, 2017 | Grant or award from the company Stock Options (right to buy) | +16,236 | 16,236 direct | Filing · EDGAR | ||
| Jun 9, 2016 | Grant or award from the company Stock Options (right to buy) | +20,000 | 20,000 direct | Filing · EDGAR | ||
| Jun 10, 2015 | Grant or award from the company Stock Options (right to buy) | +20,000 | 20,000 direct | Filing · EDGAR | ||
| Nov 25, 2014 | Grant or award from the company | +32,000 | $7.83 | $251K | 142,000 direct | Filing · EDGAR |
| Jun 12, 2014 | Grant or award from the company Stock Options (right to buy) | +15,000 | 15,000 direct | Filing · EDGAR | ||
| Mar 12, 2014 | Grant or award from the company | +110,000 | $2.21 | $243K | 110,000 direct | Filing · EDGAR |
| Jun 13, 2013 | Grant or award from the company Stock Options (right to buy) | +15,000 | 15,000 direct | Filing · EDGAR | ||
| Jun 13, 2012 | Grant or award from the company Stock Option (right to buy) | +30,000 | 30,000 direct | Filing · EDGAR |
Cascadian Therapeutics Director · filings 2013 to 2018 · bought $98K
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Mar 9, 2018 | Tendered in a change of control | −37,394 | $0.00 | $4 | 0 direct | Filing · EDGAR |
| Mar 9, 2018 | Returned to the company Restricted Stock Units | −13,927 | 0 direct | Filing · EDGAR | ||
| Sep 24, 2017 | Option or RSU exercised or converted | +2,375 | 37,988 direct | Filing · EDGAR | ||
| Sep 24, 2017 | Shares withheld for tax or exercise price | −594 | $3.94 | $2K | 37,394 direct | Filing · EDGAR |
| Sep 24, 2017 | Option or RSU exercised or converted Restricted Share Unit (RSU) | −2,375 | 0 direct | Filing · EDGAR | ||
| Jun 24, 2017 | Option or RSU exercised or converted | +9,058 | 37,878 direct | Filing · EDGAR | ||
| Jun 24, 2017 | Shares withheld for tax or exercise price | −2,265 | $3.78 | $9K | 35,613 direct | Filing · EDGAR |
| Jun 24, 2017 | Option or RSU exercised or converted Restricted Share Unit (RSU) | −9,058 | 0 direct | Filing · EDGAR | ||
| Jun 12, 2017 | Option or RSU exercised or converted | +2,148 | 29,357 direct | Filing · EDGAR | ||
| Jun 12, 2017 | Shares withheld for tax or exercise price | −537 | $3.34 | $2K | 28,820 direct | Filing · EDGAR |
| Jun 12, 2017 | Option or RSU exercised or converted Restricted Share Unit (RSU) | −2,148 | 0 direct | Filing · EDGAR | ||
| Jun 9, 2017 | Grant or award from the company Restricted Share Unit (RSU) | +13,927 | 13,927 direct | Filing · EDGAR | ||
| Feb 2, 2017 | Open-market or private purchase | +23,000 | $4.24 | $98K | 27,209 direct | Filing · EDGAR |
| Jun 24, 2016 | Grant or award from the company Restricted Share Unit (RSU) | +54,347 | 54,347 direct | Filing · EDGAR | ||
| Jun 6, 2016 | Option or RSU exercised or converted | +2,723 | 27,890 direct | Filing · EDGAR | ||
| Jun 6, 2016 | Shares withheld for tax or exercise price | −681 | $7.38 | $5K | 27,209 direct | Filing · EDGAR |
| Jun 6, 2016 | Option or RSU exercised or converted Restricted Share Unit (RSU) | −2,723 | 0 direct | Filing · EDGAR | ||
| Sep 24, 2015 | Grant or award from the company Restricted Share Unit (RSU) | +14,245 | 14,245 direct | Filing · EDGAR | ||
| Sep 5, 2015 | Option or RSU exercised or converted | +17,341 | 17,341 direct | Filing · EDGAR | ||
| Sep 5, 2015 | Shares withheld for tax or exercise price | −4,336 | $3.25 | $14K | 13,005 direct | Filing · EDGAR |
| Sep 5, 2015 | Option or RSU exercised or converted Restricted Share Unit (RSU) | −17,341 | 0 direct | Filing · EDGAR | ||
| Jun 12, 2015 | Grant or award from the company Restricted Share Unit (RSU) | +12,886 | 12,886 direct | Filing · EDGAR | ||
| Jun 6, 2014 | Grant or award from the company Restricted Share Unit (RSU) | +16,339 | 16,339 direct | Filing · EDGAR | ||
| Sep 5, 2013 | Grant or award from the company Restricted Share Unit (RSU) | +17,341 | 17,341 direct | Filing · EDGAR |
Kalobios Pharmaceuticals Director · filings 2012 to 2015
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Jul 10, 2015 | Grant or award from the company Stock Option (right to buy) | +5,000 | 5,000 direct | Filing · EDGAR | ||
| Jun 18, 2014 | Grant or award from the company Stock Option (right to buy) | +20,000 | 20,000 direct | Filing · EDGAR | ||
| Apr 30, 2013 | Grant or award from the company Stock Option (right to buy) | +15,000 | 15,000 direct | Filing · EDGAR |
Santarus Director · filings 2005 to 2014 · bought $2M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Jan 2, 2014 | Tendered in a change of control | −335,500 | $32.00 | $10.7M | 0 direct | Filing · EDGAR |
| Jan 2, 2014 | Returned to the company Stock Options (right to buy) | −34,500 | $10.07 | $347K | 0 direct | Filing · EDGAR |
| Jan 2, 2014 | Returned to the company Stock Options (right to buy) | −34,500 | $25.27 | $872K | 0 direct | Filing · EDGAR |
| Jan 2, 2014 | Returned to the company Stock Options (right to buy) | −34,500 | $28.88 | $996K | 0 direct | Filing · EDGAR |
| Jan 2, 2014 | Returned to the company Stock Options (right to buy) | −32,000 | $28.67 | $917K | 0 direct | Filing · EDGAR |
| Jan 2, 2014 | Returned to the company Stock Options (right to buy) | −34,500 | $26.68 | $920K | 0 direct | Filing · EDGAR |
| Jan 2, 2014 | Returned to the company Stock Options (right to buy) | −32,500 | $25.27 | $821K | 0 direct | Filing · EDGAR |
| Jan 2, 2014 | Returned to the company Stock Options (right to buy) | −35,000 | $26.76 | $937K | 0 direct | Filing · EDGAR |
| Jun 11, 2013 | Grant or award from the company Stock Option (right to buy) | +34,500 | 34,500 direct | Filing · EDGAR | ||
| Dec 18, 2012 | Open-market or private purchase | +185,000 | $10.88 | $2M | 335,500 direct | Filing · EDGAR |
| Jun 13, 2012 | Grant or award from the company Stock Option (right to buy) | +34,500 | 34,500 direct | Filing · EDGAR | ||
| Mar 9, 2012 | Option or RSU exercised or converted | +15,000 | $3.00 | $45K | 15,000 direct | Filing · EDGAR |
| Mar 9, 2012 | Option or RSU exercised or converted | +34,500 | $2.02 | $70K | 49,500 direct | Filing · EDGAR |
| Mar 9, 2012 | Option or RSU exercised or converted | +32,000 | $1.18 | $38K | 81,500 direct | Filing · EDGAR |
| Mar 9, 2012 | Option or RSU exercised or converted | +34,500 | $2.38 | $82K | 116,000 direct | Filing · EDGAR |
| Mar 9, 2012 | Option or RSU exercised or converted | +34,500 | $2.47 | $85K | 150,500 direct | Filing · EDGAR |
| Mar 9, 2012 | Option or RSU exercised or converted Stock Options (right to buy) | −15,000 | 0 direct | Filing · EDGAR | ||
| Mar 9, 2012 | Option or RSU exercised or converted Stock Options (right to buy) | −34,500 | 0 direct | Filing · EDGAR | ||
| Mar 9, 2012 | Option or RSU exercised or converted Stock Options (right to buy) | −32,000 | 0 direct | Filing · EDGAR | ||
| Mar 9, 2012 | Option or RSU exercised or converted Stock Options (right to buy) | −34,500 | 0 direct | Filing · EDGAR | ||
| Mar 9, 2012 | Option or RSU exercised or converted Stock Options (right to buy) | −34,500 | 0 direct | Filing · EDGAR | ||
| Jun 15, 2011 | Grant or award from the company Stock Option (right to buy) | +34,500 | 34,500 direct | Filing · EDGAR | ||
| Mar 10, 2011 | Grant or award from the company Stock Options (right to buy) | +32,000 | 32,000 direct | Filing · EDGAR | ||
| Jun 10, 2010 | Grant or award from the company Stock Option (right to buy) | +34,500 | 34,500 direct | Filing · EDGAR | ||
| Jun 11, 2009 | Grant or award from the company Stock Option (right to buy) | +34,500 | 34,500 direct | Filing · EDGAR | ||
| Mar 16, 2009 | Grant or award from the company Stock Options (right to buy) | +32,000 | 32,000 direct | Filing · EDGAR | ||
| Jun 12, 2008 | Grant or award from the company Stock Option (right to buy) | +34,500 | 34,500 direct | Filing · EDGAR | ||
| Jun 14, 2007 | Grant or award from the company Stock Option (right to buy) | +34,500 | 34,500 direct | Filing · EDGAR | ||
| Jun 7, 2006 | Grant or award from the company Stock Option (right to buy) | +32,500 | 32,500 direct | Filing · EDGAR | ||
| Jun 9, 2005 | Grant or award from the company Stock Option (right to buy) | +15,000 | 15,000 direct | Filing · EDGAR | ||
| Mar 17, 2005 | Grant or award from the company Stock Option (right to buy) | +35,000 | 35,000 direct | Filing · EDGAR |
Mast Therapeutics Director · filings 2012 to 2013
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Jun 19, 2013 | Grant or award from the company Stock Option (Right to Buy) | +62,451 | 62,451 direct | Filing · EDGAR | ||
| Sep 5, 2012 | Grant or award from the company Stock Option (Right to Buy) | +18,895 | 18,895 direct | Filing · EDGAR | ||
| Sep 5, 2012 | Grant or award from the company Stock Option (Right to Buy) | +14,171 | 14,171 direct | Filing · EDGAR |
Onyx Pharmaceuticals EVP, R&D and Tech. Operations · filings 2010 to 2012 · sold $388K
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Jul 25, 2012 | Sale under a 10b5-1 plan | −5,241 | $73.97 | $388K | 77,756 direct | Filing · EDGAR |
| Apr 2, 2012 | Returned to the company | −757 | $36.58 | $28K | 82,997 direct | Filing · EDGAR |
| Mar 30, 2012 | Grant or award from the company | +9,800 | 66,604 direct | Filing · EDGAR | ||
| Mar 30, 2012 | Grant or award from the company | +17,150 | 83,754 direct | Filing · EDGAR | ||
| Mar 30, 2012 | Grant or award from the company Stock Option (Right to Buy) | +49,700 | 49,700 direct | Filing · EDGAR | ||
| Feb 1, 2012 | Shares withheld for tax or exercise price | −2,098 | $41.98 | $88K | 56,804 direct | Filing · EDGAR |
| Mar 31, 2011 | Grant or award from the company | +6,000 | 35,737 direct | Filing · EDGAR | ||
| Mar 31, 2011 | Grant or award from the company | +22,500 | 58,237 direct | Filing · EDGAR | ||
| Mar 31, 2011 | Grant or award from the company Stock Option (Right to Buy) | +42,000 | 42,000 direct | Filing · EDGAR | ||
| Feb 1, 2011 | Shares withheld for tax or exercise price | −2,113 | $35.82 | $76K | 29,737 direct | Filing · EDGAR |
| Feb 1, 2010 | Grant or award from the company | +16,500 | 31,850 direct | Filing · EDGAR | ||
| Feb 1, 2010 | Grant or award from the company Stock Option (Right to Buy) | +115,500 | 115,500 direct | Filing · EDGAR |
Affymax Director · filings 2006 to 2012
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Jun 13, 2012 | Grant or award from the company Stock Option (Right to Buy) | +12,000 | 12,000 direct | Filing · EDGAR | ||
| May 25, 2011 | Grant or award from the company Stock Option (Right to Buy) | +12,000 | 12,000 direct | Filing · EDGAR | ||
| May 24, 2010 | Grant or award from the company Stock Option (Right to Buy) | +7,500 | 7,500 direct | Filing · EDGAR | ||
| May 28, 2009 | Grant or award from the company Stock Option (Right to Buy) | +2,500 | 2,500 direct | Filing · EDGAR | ||
| May 22, 2008 | Grant or award from the company Stock Option (Right to Buy) | +2,500 | 2,500 direct | Filing · EDGAR | ||
| May 31, 2007 | Grant or award from the company Stock Option (Right to Buy) | +2,500 | 2,500 direct | Filing · EDGAR |
Bio Rad Laboratories Director · filings 2010 to 2010
No transactions in the filings read; Form 144 notices are listed above.
ARCA biopharma C.E.O · filings 2003 to 2010 · bought $19K
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Feb 5, 2010 | Grant or award from the company Option to Purchase Common Stock | +3,500 | 3,500 direct | Filing · EDGAR | ||
| Feb 27, 2009 | Grant or award from the company Option to Purchase Common Stock | +7,500 | 7,500 direct | Filing · EDGAR | ||
| May 30, 2008 | Other acquisition or disposition (see the filing) | +147 | $13.09 | $2K | 3,580 direct | Filing · EDGAR |
| Mar 24, 2008 | Open-market or private purchase | +29,000 | $0.67 | $19K | 57,289 direct | Filing · EDGAR |
| Feb 29, 2008 | Other acquisition or disposition (see the filing) | +576 | $28.39 | $16K | 3,580 direct | Filing · EDGAR |
| Feb 1, 2008 | Grant or award from the company Non-Qualified Stock Option (right to buy) | +141,667 | 141,667 direct | Filing · EDGAR | ||
| Feb 1, 2008 | Grant or award from the company Incentive Stock Option (right to buy) | +58,333 | 58,333 direct | Filing · EDGAR | ||
| Aug 31, 2007 | Discretionary trade in a company plan | +1,598 | $1.85 | $3K | 28,289 direct | Filing · EDGAR |
| May 31, 2007 | Discretionary trade in a company plan | +5,649 | $2.90 | $16K | 26,691 direct | Filing · EDGAR |
| Feb 1, 2007 | Grant or award from the company Non Qualified Stock Option (right to buy) | +300,000 | 300,000 direct | Filing · EDGAR | ||
| Aug 31, 2006 | Discretionary trade in a company plan | +292 | $14.20 | $4K | 21,042 direct | Filing · EDGAR |
| Aug 1, 2006 | Grant or award from the company Non-Qualified Stock Option (right to buy) | +371,960 | 371,960 direct | Filing · EDGAR | ||
| Aug 1, 2006 | Grant or award from the company Incentive Stock Option (right to buy) | +3,040 | 3,040 direct | Filing · EDGAR | ||
| May 31, 2006 | Discretionary trade in a company plan | +1,132 | $13.90 | $16K | 4,423 direct | Filing · EDGAR |
| Aug 31, 2005 | Discretionary trade in a company plan | +913 | $6.33 | $6K | 3,291 direct | Filing · EDGAR |
| Aug 1, 2005 | Grant or award from the company Non-Qualified Stock Option (right to buy) | +450,000 | 450,000 direct | Filing · EDGAR | ||
| May 31, 2005 | Discretionary trade in a company plan | +2,378 | $6.30 | $15K | 2,378 direct | Filing · EDGAR |
| Jan 7, 2005 | Grant or award from the company Non-Qualified Stock Option (right to buy) | +284,822 | 284,822 direct | Filing · EDGAR | ||
| Jan 7, 2005 | Grant or award from the company Incentive Stock Option (right to buy) | +15,178 | 15,178 direct | Filing · EDGAR | ||
| Aug 31, 2004 | Discretionary trade in a company plan | +361 | $7.57 | $3K | 361 direct | Filing · EDGAR |
| May 28, 2004 | Discretionary trade in a company plan | +999 | $7.40 | $7K | 999 direct | Filing · EDGAR |
| May 7, 2004 | Grant or award from the company Non-Qualified Stock Option (right to buy) | +350,000 | 350,000 direct | Filing · EDGAR | ||
| May 7, 2004 | Grant or award from the company Non-Qualified Stock Option (right to buy) | +138,419 | 138,419 direct | Filing · EDGAR | ||
| May 7, 2004 | Grant or award from the company Incentive Stock Option (right to buy) | +11,581 | 11,581 direct | Filing · EDGAR | ||
| Feb 27, 2004 | Discretionary trade in a company plan | +703 | $10.45 | $7K | 703 direct | Filing · EDGAR |
All 148 Forms 3, 4, 5 and 144
| Filed | Form | Company | Links |
|---|---|---|---|
| Sep 28, 2026 | Form 3 | Lisata Therapeutics LSTA | Filing · EDGAR |
| Sep 2, 2026 | Form 4 | Jazz Pharmaceuticals JAZZ | Filing · EDGAR |
| Aug 31, 2026 | Form 144 | Jazz Pharmaceuticals JAZZ | Filing · EDGAR |
| Aug 7, 2026 | Form 4 | Jazz Pharmaceuticals JAZZ | Filing · EDGAR |
| Jun 18, 2026 | Form 4 | Structure Therapeutics GPCR | Filing · EDGAR |
| Jun 8, 2026 | Form 4 | Royalty Pharma RPRX | Filing · EDGAR |
| May 4, 2026 | Form 4 | Gilead Sciences GILD | Filing · EDGAR |
| Mar 2, 2026 | Form 4 | Jazz Pharmaceuticals JAZZ | Filing · EDGAR |
| Dec 10, 2025 | Form 3 | Jazz Pharmaceuticals JAZZ | Filing · EDGAR |
| Jun 25, 2025 | Form 4 | Structure Therapeutics GPCR | Filing · EDGAR |
| May 14, 2025 | Form 4 | Royalty Pharma RPRX | Filing · EDGAR |
| May 8, 2025 | Form 4 | Gilead Sciences GILD | Filing · EDGAR |
| Jun 27, 2024 | Form 4 | Structure Therapeutics GPCR | Filing · EDGAR |
| Jun 10, 2024 | Form 4 | Royalty Pharma RPRX | Filing · EDGAR |
| May 9, 2024 | Form 4 | Gilead Sciences GILD | Filing · EDGAR |
| Feb 6, 2024 | Form 4 | Gilead Sciences GILD | Filing · EDGAR |
| Feb 6, 2024 | Form 3 | Gilead Sciences GILD | Filing · EDGAR |
| Dec 15, 2023 | Form 4 | Seagen | Filing · EDGAR |
| Aug 4, 2023 | Form 4 | Structure Therapeutics GPCR | Filing · EDGAR |
| Aug 4, 2023 | Form 3 | Structure Therapeutics GPCR | Filing · EDGAR |
| Jun 26, 2023 | Form 4 | Royalty Pharma RPRX | Filing · EDGAR |
| Jun 2, 2023 | Form 4 | Seagen | Filing · EDGAR |
| Oct 6, 2022 | Form 4 | Global Blood Therapeutics | Filing · EDGAR |
| Sep 29, 2022 | Form 4 | Global Blood Therapeutics | Filing · EDGAR |
| Sep 6, 2022 | Form 4 | Global Blood Therapeutics | Filing · EDGAR |
| Aug 3, 2022 | Form 4 | Global Blood Therapeutics | Filing · EDGAR |
| Jun 24, 2022 | Form 4 | Royalty Pharma RPRX | Filing · EDGAR |
| May 17, 2022 | Form 4 | Seagen | Filing · EDGAR |
| Mar 3, 2022 | Form 4 | Global Blood Therapeutics | Filing · EDGAR |
| Feb 3, 2022 | Form 4 | Global Blood Therapeutics | Filing · EDGAR |
| Jan 6, 2022 | Form 4/A | Global Blood Therapeutics | Filing · EDGAR |
| Sep 24, 2021 | Form 4/A | Global Blood Therapeutics | Filing · EDGAR |
| Sep 3, 2021 | Form 4 | Global Blood Therapeutics | Filing · EDGAR |
| Aug 3, 2021 | Form 4 | Global Blood Therapeutics | Filing · EDGAR |
| Jun 29, 2021 | Form 4 | Royalty Pharma RPRX | Filing · EDGAR |
| May 18, 2021 | Form 4 | Seagen | Filing · EDGAR |
| Mar 3, 2021 | Form 4 | Global Blood Therapeutics | Filing · EDGAR |
| Feb 3, 2021 | Form 4 | Global Blood Therapeutics | Filing · EDGAR |
| Aug 18, 2020 | Form 4 | Seagen | Filing · EDGAR |
| Aug 18, 2020 | Form 3 | Seagen | Filing · EDGAR |
| Aug 17, 2020 | Form 4 | Royalty Pharma RPRX | Filing · EDGAR |
| Aug 10, 2020 | Form 3 | Royalty Pharma RPRX | Filing · EDGAR |
| Aug 4, 2020 | Form 4 | Global Blood Therapeutics | Filing · EDGAR |
| Jul 2, 2020 | Form 4 | Portola Pharmaceuticals | Filing · EDGAR |
| Jun 15, 2020 | Form 4 | Portola Pharmaceuticals | Filing · EDGAR |
| Jun 8, 2020 | Form 4 | Amicus Therapeutics | Filing · EDGAR |
| Jun 3, 2020 | Form 4 | Global Blood Therapeutics | Filing · EDGAR |
| Apr 29, 2020 | Form 4 | Global Blood Therapeutics | Filing · EDGAR |
| Feb 20, 2020 | Form 4 | Global Blood Therapeutics | Filing · EDGAR |
| Feb 4, 2020 | Form 4 | Global Blood Therapeutics | Filing · EDGAR |
| Jan 23, 2020 | Form 4 | Global Blood Therapeutics | Filing · EDGAR |
| Dec 17, 2019 | Form 4 | Global Blood Therapeutics | Filing · EDGAR |
| Dec 9, 2019 | Form 4 | Global Blood Therapeutics | Filing · EDGAR |
| Oct 2, 2019 | Form 4 | Portola Pharmaceuticals | Filing · EDGAR |
| Oct 2, 2019 | Form 3 | Portola Pharmaceuticals | Filing · EDGAR |
| Aug 5, 2019 | Form 4 | Global Blood Therapeutics | Filing · EDGAR |
| Jul 1, 2019 | Form 4 | Amicus Therapeutics | Filing · EDGAR |
| Apr 10, 2019 | Form 4 | Global Blood Therapeutics | Filing · EDGAR |
| Feb 5, 2019 | Form 4 | Global Blood Therapeutics | Filing · EDGAR |
| Aug 3, 2018 | Form 4 | Global Blood Therapeutics | Filing · EDGAR |
| Jul 17, 2018 | Form 4 | Global Blood Therapeutics | Filing · EDGAR |
| Jun 11, 2018 | Form 4 | Amicus Therapeutics | Filing · EDGAR |
| Mar 13, 2018 | Form 4 | Cascadian Therapeutics | Filing · EDGAR |
| Feb 16, 2018 | Form 4 | Global Blood Therapeutics | Filing · EDGAR |
| Feb 2, 2018 | Form 4 | Global Blood Therapeutics | Filing · EDGAR |
| Jan 26, 2018 | Form 4 | Global Blood Therapeutics | Filing · EDGAR |
| Jan 18, 2018 | Form 4 | Global Blood Therapeutics | Filing · EDGAR |
| Sep 26, 2017 | Form 4 | Cascadian Therapeutics | Filing · EDGAR |
| Aug 14, 2017 | Form 4 | Global Blood Therapeutics | Filing · EDGAR |
| Aug 3, 2017 | Form 4 | Global Blood Therapeutics | Filing · EDGAR |
| Jun 27, 2017 | Form 4 | Cascadian Therapeutics | Filing · EDGAR |
| Jun 16, 2017 | Form 4/A | Amicus Therapeutics | Filing · EDGAR |
| Jun 15, 2017 | Form 4 | Amicus Therapeutics | Filing · EDGAR |
| Jun 13, 2017 | Form 4 | Cascadian Therapeutics | Filing · EDGAR |
| Feb 14, 2017 | Form 5 | Global Blood Therapeutics | Filing · EDGAR |
| Feb 10, 2017 | Form 5 | Cascadian Therapeutics | Filing · EDGAR |
| Feb 3, 2017 | Form 4 | Cascadian Therapeutics | Filing · EDGAR |
| Jan 19, 2017 | Form 4 | Global Blood Therapeutics | Filing · EDGAR |
| Dec 16, 2016 | Form 4 | Global Blood Therapeutics | Filing · EDGAR |
| Jun 28, 2016 | Form 4 | Cascadian Therapeutics | Filing · EDGAR |
| Jun 13, 2016 | Form 4 | Amicus Therapeutics | Filing · EDGAR |
| Feb 3, 2016 | Form 4 | Global Blood Therapeutics | Filing · EDGAR |
| Jan 7, 2016 | Form 4 | Global Blood Therapeutics | Filing · EDGAR |
| Sep 28, 2015 | Form 4 | Cascadian Therapeutics | Filing · EDGAR |
| Sep 9, 2015 | Form 4 | Cascadian Therapeutics | Filing · EDGAR |
| Aug 11, 2015 | Form 3 | Global Blood Therapeutics | Filing · EDGAR |
| Jul 14, 2015 | Form 4 | Kalobios Pharmaceuticals | Filing · EDGAR |
| Jun 16, 2015 | Form 4 | Cascadian Therapeutics | Filing · EDGAR |
| Jun 12, 2015 | Form 4 | Amicus Therapeutics | Filing · EDGAR |
| Dec 15, 2014 | Form 4 | Amicus Therapeutics | Filing · EDGAR |
| Jun 20, 2014 | Form 4 | Kalobios Pharmaceuticals | Filing · EDGAR |
| Jun 16, 2014 | Form 4 | Amicus Therapeutics | Filing · EDGAR |
| Jun 10, 2014 | Form 4 | Cascadian Therapeutics | Filing · EDGAR |
| Mar 12, 2014 | Form 4 | Amicus Therapeutics | Filing · EDGAR |
| Jan 6, 2014 | Form 4 | Santarus | Filing · EDGAR |
| Sep 6, 2013 | Form 4 | Cascadian Therapeutics | Filing · EDGAR |
| Sep 6, 2013 | Form 3 | Cascadian Therapeutics | Filing · EDGAR |
| Jun 21, 2013 | Form 4 | Mast Therapeutics | Filing · EDGAR |
| Jun 17, 2013 | Form 4 | Amicus Therapeutics | Filing · EDGAR |
| Jun 12, 2013 | Form 4 | Santarus | Filing · EDGAR |
| May 2, 2013 | Form 4 | Kalobios Pharmaceuticals | Filing · EDGAR |
| May 2, 2013 | Form 3/A | Kalobios Pharmaceuticals | Filing · EDGAR |
| Dec 19, 2012 | Form 4 | Santarus | Filing · EDGAR |
| Sep 7, 2012 | Form 4 | Mast Therapeutics | Filing · EDGAR |
| Sep 7, 2012 | Form 3 | Mast Therapeutics | Filing · EDGAR |
| Aug 10, 2012 | Form 3 | Kalobios Pharmaceuticals | Filing · EDGAR |
| Jul 27, 2012 | Form 4 | Onyx Pharmaceuticals | Filing · EDGAR |
| Jun 18, 2012 | Form 4 | Affymax | Filing · EDGAR |
| Jun 15, 2012 | Form 4 | Amicus Therapeutics | Filing · EDGAR |
| Jun 15, 2012 | Form 3 | Amicus Therapeutics | Filing · EDGAR |
| Jun 14, 2012 | Form 4 | Santarus | Filing · EDGAR |
| Apr 3, 2012 | Form 4 | Onyx Pharmaceuticals | Filing · EDGAR |
| Mar 12, 2012 | Form 4 | Santarus | Filing · EDGAR |
| Feb 3, 2012 | Form 4 | Onyx Pharmaceuticals | Filing · EDGAR |
| Jun 16, 2011 | Form 4 | Santarus | Filing · EDGAR |
| May 26, 2011 | Form 4 | Affymax | Filing · EDGAR |
| Apr 4, 2011 | Form 4 | Onyx Pharmaceuticals | Filing · EDGAR |
| Mar 11, 2011 | Form 4 | Santarus | Filing · EDGAR |
| Feb 3, 2011 | Form 4 | Onyx Pharmaceuticals | Filing · EDGAR |
| Jun 11, 2010 | Form 4 | Santarus | Filing · EDGAR |
| May 26, 2010 | Form 4 | Affymax | Filing · EDGAR |
| Mar 25, 2010 | Form 3 | Bio Rad Laboratories | Filing · EDGAR |
| Feb 9, 2010 | Form 4 | ARCA biopharma | Filing · EDGAR |
| Feb 3, 2010 | Form 4 | Onyx Pharmaceuticals | Filing · EDGAR |
| Feb 3, 2010 | Form 3 | Onyx Pharmaceuticals | Filing · EDGAR |
| Jun 12, 2009 | Form 4 | Santarus | Filing · EDGAR |
| May 29, 2009 | Form 4 | Affymax | Filing · EDGAR |
| Mar 17, 2009 | Form 4 | Santarus | Filing · EDGAR |
| Mar 3, 2009 | Form 4 | ARCA biopharma | Filing · EDGAR |
| Feb 17, 2009 | Form 5 | ARCA biopharma | Filing · EDGAR |
| Jun 16, 2008 | Form 4 | Santarus | Filing · EDGAR |
| May 23, 2008 | Form 4 | Affymax | Filing · EDGAR |
| Mar 25, 2008 | Form 4 | ARCA biopharma | Filing · EDGAR |
| Feb 4, 2008 | Form 4 | ARCA biopharma | Filing · EDGAR |
| Jun 15, 2007 | Form 4 | Santarus | Filing · EDGAR |
| May 31, 2007 | Form 4 | Affymax | Filing · EDGAR |
| Feb 2, 2007 | Form 4 | ARCA biopharma | Filing · EDGAR |
| Dec 14, 2006 | Form 3 | Affymax | Filing · EDGAR |
| Aug 2, 2006 | Form 4 | ARCA biopharma | Filing · EDGAR |
| Jun 9, 2006 | Form 4 | Santarus | Filing · EDGAR |
| Mar 7, 2006 | Form 4/A | ARCA biopharma | Filing · EDGAR |
| Aug 3, 2005 | Form 4 | ARCA biopharma | Filing · EDGAR |
| Jun 10, 2005 | Form 4 | Santarus | Filing · EDGAR |
| Mar 18, 2005 | Form 4 | Santarus | Filing · EDGAR |
| Mar 18, 2005 | Form 3 | Santarus | Filing · EDGAR |
| Jan 12, 2005 | Form 4 | ARCA biopharma | Filing · EDGAR |
| Jun 1, 2004 | Form 4 | ARCA biopharma | Filing · EDGAR |
| Jun 25, 2003 | Form 4 | ARCA biopharma | Filing · EDGAR |
Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.
Data on this page was fetched . The filing on SEC.gov is the record.